University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
NCT Number: NCT01659398
The aim of this study is to investigate whether enhanced external counterpulsation (EECP) therapy for 7 consecutive weeks will improve cerebral blood flow and possibly over time enhance or slow down breakdown of cognitive function in patients diagnosed with mild cognitive impairment (MCI).
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Early Phase 1
Kansas City, Kansas, 66160, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
Time frame: Baseline, Week 7, 6 Month
Change in cognitive function measured using the Alzheimer's Disease Assessment Scale-cognitive sub-scale (ADAS-cog). Scale is used to determine patient's mental status. The scale has 11 parts and scores range from 0 (no impairment) to 70 (severe impairment).
Time frame: Baseline to Week 7
Time frame: Baseline to Week 7
Time frame: Baseline to week 7
Looking for future studies?
Notify MePatrick Moriarty, MD, FACP, FACC
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03649724
Alzheimer Disease, Brain Diseases
Boca Raton, Florida, United States
View Trial DetailsNCT02720445
Alzheimer Disease, Brain Diseases
Scottsdale, Arizona, United States
View Trial DetailsNCT04296565
Alzheimer Disease, Behavior
Palo Alto, California, United States
View Trial DetailsNCT05637801
Alzheimer Disease, Alzheimer Disease 1
Gilbert, Arizona, United States
View Trial Details